Mary Alikian
Papers
1
Total Citations
15
H-Index
1
About
Mary Alikian is a molecular biologist whose work centers on improving the molecular monitoring of hematological malignancies, particularly those driven by the BCR-ABL1 fusion gene. Her major contribution lies in advancing the precision and practicality of reverse transcription quantitative polymerase chain reaction (RT-qPCR), the gold-standard tool for tracking minimal residual disease in patients with chronic myeloid leukemia. Her highly cited 2012 paper, “Fast‐mode duplex qPCR for BCR-ABL1 molecular monitoring: Innovation, automation, and harmonization,” addresses a critical clinical need: making this sensitive assay faster, more automated, and more consistent across laboratories. By tackling the challenges of standardization and workflow efficiency, Alikian’s work directly supports the harmonization of international monitoring protocols, enabling more reliable comparisons of patient outcomes across treatment centers. Her research bridges the gap between cutting-edge molecular diagnostics and routine clinical application, ensuring that sensitive disease detection is both accessible and reproducible. With 15 citations on this key paper alone, Alikian has established herself as a thoughtful contributor to the field of molecular hematology, dedicated to refining the tools that guide life-saving therapeutic decisions for patients with BCR-ABL1-positive leukemias.
Research Focus
Key Achievements
Top Papers
- 1